The science does not yet support regulatory approval of amyloid-targeting therapies for Alzheimer's disease based solely on biomarker evidence.

ABSTRACT:

SUBMITTER: Planche V 

PROVIDER: S-EPMC12004391 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature